Phase III study of AstraZeneca PD-L1 in locally advanced cervical cancer fails

Author: Pickup

On March 24, AstraZeneca announced that the Phase III CALLA study of PD-L1 monoclonal antibody Imfinzi (durvalumab) combined with chemoradiotherapy (CRT) in the treatment of locally advanced cervical cancer failed to improve progression-free survival (PFS) the primary endpoint

Safety and tolerability were consistent between the two arms in this trial, and no new unexpected safety results were observed

The CALLA study is a randomized, multicenter, double-blind, global phase III clinical trial in 770 patients with locally advanced cervical cancer who received standard-of-care CRT plus either 1500 mg fixed-dose Imfinzi or placebo every four weeks.

The trial is being conducted at 120 centers in 15 countries, including the United States, Europe, Latin America, Africa and Asia

Cervical cancer is the eighth most common and ninth deadliest cancer worldwide, with approximately 600,000 cases diagnosed each year

Note: The original text has been deleted